<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215146</url>
  </required_header>
  <id_info>
    <org_study_id>REO 028</org_study_id>
    <secondary_id>PrE0113</secondary_id>
    <nct_id>NCT04215146</nct_id>
  </id_info>
  <brief_title>A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study</brief_title>
  <official_title>A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncolytics Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PrECOG, LLC.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oncolytics Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the possible anti-cancer effect of pelareorep in&#xD;
      combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer&#xD;
      called Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2&#xD;
      negative(HER2-) breast cancer, which is either locally advanced or has metastasized (cancer&#xD;
      that has spread in your body). The study will investigate if pelareorep in combination with&#xD;
      paclitaxel and avelumab is more effective than paclitaxel alone, or pelareorep and&#xD;
      paclitaxel. The safety of the combination treatments will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label randomized Phase 2, 3-cohort study to evaluate the safety and efficacy&#xD;
      of pelareorep, paclitaxel and avelumab in Hormone Receptor+ (HR+)/Human Epidermal Growth&#xD;
      Factor Receptor 2 negative (HER2-) with endocrine-refractory metastatic breast cancer.&#xD;
&#xD;
      Patients will be randomized to one of three treatment cohorts: paclitaxel alone, pelareorep +&#xD;
      paclitaxel, or pelareorep + paclitaxel + avelumab. A three patient safety run-in will be&#xD;
      conducted in the cohort for pelareorep + paclitaxel + avelumab prior to beginning&#xD;
      randomization into all three cohorts.&#xD;
&#xD;
      Patients will give mandatory blood samples and optional tumor biopsies, which will be&#xD;
      analyzed for biomarkers to determine the immunological changes within the tumor&#xD;
      microenvironment and peripheral blood in patients treated with paclitaxel alone, in&#xD;
      combination with pelareorep, and in combination with pelareorep and avelumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>at week 16.</time_frame>
    <description>Overall response rate at week 16 according to RECIST V1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To describe the safety and tolerability of the combinations of pelareorep, paclitaxel and avelumab as graded by the NCI CTCAE v. 5.0.</measure>
    <time_frame>From start of study treatment to 30 days after of last dose of study treatment.</time_frame>
    <description>Type, incidence, severity (as graded by the NCI CTCAE v. 5.0), seriousness and attribution to the study medications of AEs and any laboratory abnormalities.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Changes in the peripheral and tumor T cell clonality.</measure>
    <time_frame>Up to 2 years of study treatment</time_frame>
    <description>Assessed by T cell receptor (CDR3 variable chain) sequencing in all patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 2 years of study participation</time_frame>
    <description>Overall response rate according to RECIST V1.1</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years of study participation</time_frame>
    <description>Overall Survival assessed at end of study</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Breast Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive paclitaxel alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pelareorep + paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pelareorep + paclitaxel + avelumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 80 mg/m^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pelareorep</intervention_name>
    <description>Pelareorep 4.5 x 10^10 TCID50 1-hour IV infusion days 1, 2, 8, 9, and 15, 16 of a 28-day cycle.</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients ≥ 18 years of age at the time of signing the informed consent form&#xD;
             (ICF).&#xD;
&#xD;
          2. Must have a histological/cytological diagnosis of breast cancer. Disease must be:&#xD;
&#xD;
               -  Positive for estrogen receptor (ER) and/or progesterone receptor (PgR) as defined&#xD;
                  by&#xD;
&#xD;
                  ≥ 1% tumor cell nuclei immunoreactive.&#xD;
&#xD;
               -  Negative for HER2 amplification / overexpression as defined per the American&#xD;
                  Society of Clinical Oncology - College of American Pathologists (ASCO-CAP)&#xD;
                  guidelines. However, patients with HER2 equivocal disease for whom HER2 targeted&#xD;
                  therapy isn't indicated are also eligible for enrollment.&#xD;
&#xD;
          3. ECOG performance status of 0-1&#xD;
&#xD;
          4. Must have unresectable locally advanced or metastatic disease, for which no curative&#xD;
             therapy exists and for which systemic chemotherapy is indicated.&#xD;
&#xD;
          5. Measurable disease as defined by RECIST Version 1.1&#xD;
&#xD;
          6. Prior Hormonal Therapy:&#xD;
&#xD;
               -  Patients must have progressed on at least 1 hormone-based therapy with a CDK4/6&#xD;
                  inhibitor. Patients who received a CDK4/6 inhibitor in the adjuvant setting and&#xD;
                  progressed while on or within 6 months of discontinuation of CDK4/6 inhibitor&#xD;
                  therapy are eligible.&#xD;
&#xD;
               -  Prior mTOR inhibitor therapy is allowed but is not required.&#xD;
&#xD;
          7. Ability to understand and willingness to sign IRB-approved informed consent.&#xD;
&#xD;
          8. Willing to provide blood samples for research&#xD;
&#xD;
          9. Adequate organ function as measured by the following criteria, obtained ≤ 2 weeks&#xD;
             prior to registration:&#xD;
&#xD;
             Hematology:&#xD;
&#xD;
               -  Neutrophils ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Lymphocytes ≥ 0.8 x 10^9/L&#xD;
&#xD;
               -  INR &lt; 1.5x ULN (Unless on therapeutic anticoagulation)&#xD;
&#xD;
               -  PTT &lt; 1.5x ULN&#xD;
&#xD;
             Biochemistry:&#xD;
&#xD;
               -  Serum Creatinine ≤ 1.5x ULN&#xD;
&#xD;
               -  Total Bilirubin ≤ 1.0x ULN (unless due to Gilbert's Disease and direct bilirubin&#xD;
                  &lt;ULN)&#xD;
&#xD;
               -  ALT and AST ≤ 3x ULN (Note: ≤ 5x ULN if documented liver metastasis)&#xD;
&#xD;
               -  Proteinuria ≤ Grade 2* (using spot testing; if Grade 3 repeat with mid-stream&#xD;
                  urine; if still Grade 3 then urine collection for 24 hours to confirm Grade 0, 1&#xD;
                  or 2) *as per National Cancer Institute Common Terminology Criteria for Adverse&#xD;
                  (NCI-CTCAE)&#xD;
&#xD;
         10. Women must not be pregnant or breastfeeding since we do not know the effects of the&#xD;
             study drugs on the fetus or breastfeeding child. All sexually active females of&#xD;
             childbearing potential (not surgically sterilized and between menarche and 1 year post&#xD;
             menopause) must have a blood test to rule out pregnancy within 2 weeks prior to&#xD;
             registration.&#xD;
&#xD;
         11. Sexually active women of child-bearing potential with a non-sterilized male partner&#xD;
             must agree to use 2 methods of adequate contraception (hormonal plus barrier or 2&#xD;
             barrier forms) OR abstinence prior to study entry, for the duration of study&#xD;
             participation, and for 3 months following last dose of study drugs. Method of&#xD;
             contraception must be documented. NOTE: If a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she must inform her treating physician&#xD;
             immediately.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No major surgery within 21 days prior to beginning study treatment. Major surgery &gt;21&#xD;
             days prior to beginning study treatment is permitted provided that the patient has&#xD;
             recovered adequately to receive systemic chemotherapy. NOTE: Placement of a vascular&#xD;
             access device is not considered major surgery.&#xD;
&#xD;
          2. Patients who have received radiation treatment within 14 days of beginning study&#xD;
             treatment are excluded. Patients who have received palliative radiation ≥ 14 days&#xD;
             prior to beginning study treatment may enroll if they have recovered from all local&#xD;
             and systemic side effects to ≤ Grade 1 (NCI-CTCAE).&#xD;
&#xD;
          3. No prior chemotherapy in the advanced/metastatic setting is allowed. Patients may have&#xD;
             received chemotherapy in the (neo)adjuvant setting. Patients receiving (neo)adjuvant&#xD;
             taxanes must have a disease-free interval of at least 12 months.&#xD;
&#xD;
          4. No known active, uncontrolled or symptomatic Central Nervous System (CNS) metastases,&#xD;
             carcinomatous meningitis, or leptomeningeal disease as indicated by clinical&#xD;
             symptoms,cerebral edema, and/or progressive growth. Patients with CNS metastases&#xD;
             treated with radiation therapy (Whole-Brain Radiation Therapy [WBXRT] or Stereotactic&#xD;
             Radiotherapy [SRS]) are eligible if, &gt;28 days following completion of XRT, they show&#xD;
             stable disease on post-treatment MRI/CT, are off corticosteroids, and are&#xD;
             neurologically stable.&#xD;
&#xD;
          5. No known history of other malignancies, except for adequately treated non-melanoma&#xD;
             skin cancer or solid tumors curatively treated with no evidence of disease for &gt;3&#xD;
             years.&#xD;
&#xD;
          6. Not on chronic immunosuppressive therapy including, but not exclusively, steroids (≥&#xD;
             10 mg prednisone a day or equivalent) or monoclonal antibodies, chronic methotrexate&#xD;
             or cyclophosphamide, tacrolimus or sirolimus.&#xD;
&#xD;
          7. No known HIV infection. Testing not required in absence of clinical suspicion.&#xD;
&#xD;
          8. No known active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection or&#xD;
             undergoing anti-viral treatment. Testing for HBV/HCV is not required in absence of&#xD;
             clinical suspicion.&#xD;
&#xD;
          9. No concurrent disease or condition that would interfere with study participation or&#xD;
             safety,such as any of the following:&#xD;
&#xD;
             • Active, clinically significant infection either Grade &gt;2 by CTCAE V5.0 or requiring&#xD;
             the use of parenteral anti-microbial agents within 14 days before registration.&#xD;
&#xD;
         10. No active or history of any autoimmune disease (patients with diabetes Type 1,&#xD;
             vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive&#xD;
             treatment are eligible) or immunodeficiencies.&#xD;
&#xD;
         11. Patients may not have evidence of uncontrolled cardiovascular conditions, including&#xD;
             uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive&#xD;
             heart failure (New York Heart Association [NYHA] Class III or higher), unstable&#xD;
             angina, or myocardial infarction within the past 6 months prior to registration. NOTE:&#xD;
             Patients with asymptomatic rate-controlled atrial fibrillation may participate.&#xD;
&#xD;
         12. Patients may not have other significant diseases (for example, inflammatory bowel&#xD;
             disease), which, in the opinion of the Investigator, might impair the patient's&#xD;
             tolerance of trial treatment.&#xD;
&#xD;
         13. Patients with a known allergy to any of the study medications, their analogues, or&#xD;
             excipients in the various formulations of any agent are not eligible.&#xD;
&#xD;
         14. Patients who have contraindications to treatment with paclitaxel and/or neuropathy&#xD;
             &gt;Grade 2 are not eligible.&#xD;
&#xD;
         15. Patients who have not recovered from clinically significant acute toxicities of&#xD;
             previous therapy are not eligible, except treatment-related alopecia or stable sensory&#xD;
             neuropathy ≤ Grade 2.&#xD;
&#xD;
         16. No prior therapy with any investigational anti-cancer therapy within 30 days. Prior&#xD;
             immunotherapies are prohibited.&#xD;
&#xD;
         17. No prior therapy with checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies),&#xD;
             checkpoint agonist agents (e.g., anti-GITR, anti-OX40 antibodies) and/or another&#xD;
             active immunotherapy in breast cancer such as cancer vaccines or oncolytic virsus.&#xD;
&#xD;
         18. Patients with any serious medical or psychiatric illness that could, in the&#xD;
             Investigator's opinion, potentially interfere with the completion of the treatment&#xD;
             according to the protocol, are not eligible.&#xD;
&#xD;
         19. Patients with legal incapacity or limited legal capacity are not eligible.&#xD;
&#xD;
         20. Patients with known alcohol or drug abuse are not eligible.&#xD;
&#xD;
         21. Patients may not participate in any other therapeutic clinical trials, including those&#xD;
             with other investigational agents not included in this trial, throughout the duration&#xD;
             of this study.&#xD;
&#xD;
         22. Patients may not have any vaccine, including against SARS-COV-2 (COVID-19) &lt;14 days&#xD;
             prior to Cycle 1 Day 1 nor in the first cycle of study treatment. Inactivated vaccines&#xD;
             (including against COVID-19 or seasonal influenza) are permitted after the first cycle&#xD;
             of study treatment is complete.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carolyn Andrews</last_name>
    <phone>267-207-4070</phone>
    <email>prE0113@precogllc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasbec Sosa</last_name>
      <phone>305-243-5611</phone>
      <email>y.sosa1@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Elisa Krill-Jackson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Rogers</last_name>
      <phone>217-383-3394</phone>
      <email>Christine.Rogers@Carle.com</email>
    </contact>
    <investigator>
      <last_name>Kendrith Rowland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Comprehensive Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Conder</last_name>
      <phone>317-278-4315</phone>
      <email>econder@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Kathy Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Woolery</last_name>
      <phone>504-842-0275</phone>
      <email>Amanda.woolery@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>John Cole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Anderson</last_name>
      <phone>314-747-5209</phone>
      <email>Jill.anderson@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Clifton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yue Wang</last_name>
      <phone>732-235-8995</phone>
      <email>yw670@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Mridula George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Park</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Bernal Guarin, MD</last_name>
      <phone>718-405-8428</phone>
      <email>abernal@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Della Makower, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Rudnicki</last_name>
      <phone>716-845-4066</phone>
      <email>Karen.Rudnicki@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Ellis Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gargi Atul Joshi</last_name>
      <phone>212-824-7320</phone>
      <email>gargiatul.joshi@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Paula Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Kongmany</last_name>
      <phone>585-533-1905</phone>
      <email>April_Kongmany@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Carla Falkson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Balint, MD</last_name>
      <phone>216-983-3229</phone>
      <email>Heidi.Balint@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>James Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Wyse</last_name>
      <phone>614-685-0380</phone>
      <email>meghan.wyse@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Sagar Sardesai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Schmucker</last_name>
      <phone>215-349-8247</phone>
      <email>Lauren.Schmucker@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Hansch</last_name>
      <phone>215-600-6326</phone>
      <email>Karen.Hansch@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Maysa Abu-Khalaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shauna Souchuck</last_name>
      <phone>215-214-3786</phone>
      <email>Shauna.Souchuck@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Elias Obeid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Hazen</last_name>
      <phone>434-297-7827</phone>
      <email>SEH3AA@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Dillon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VCU/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mila McKelvey</last_name>
      <phone>804-628-5810</phone>
      <email>mckelveyms@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Masey Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Hawkins</last_name>
      <phone>304-293-7375</phone>
      <email>emily.hawkins@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Maria Hafez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 24, 2019</study_first_submitted>
  <study_first_submitted_qc>December 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Breast Cancer Metastatic</keyword>
  <keyword>Locally Advanced Breast Cancer</keyword>
  <keyword>Pelareorep</keyword>
  <keyword>Avelumab</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Reovirus</keyword>
  <keyword>Oncolytic virus</keyword>
  <keyword>HR+ breast cancer</keyword>
  <keyword>HER2- breast cancer</keyword>
  <keyword>Breast malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

